


 Cite this: *RSC Adv.*, 2021, **11**, 13014

# Exploring the utility of hybrid siloxane-phosphocholine (SiPC) liposomes as drug delivery vehicles†

 Mark B. Frampton,<sup>a</sup> ‡<sup>a</sup> Andrea Blais,<sup>a</sup> Zachary Raczewski,<sup>a</sup> Alan Castle<sup>b</sup> and Paul M. Zelisko<sup>b</sup> \*<sup>a</sup>

Hybrid siloxane-phosphocholines (SiPCs) are a unique class of lipids that possess the capacity to spontaneously form unilamellar vesicles (ULVs) that are ~100 nm in diameter upon exposure to aqueous media without the need for extrusion. These hybrid SiPCs do not negatively impact the growth of a number of bacterial strains and were subsequently explored as candidates for the delivery of a model compound, calcein. Liposomes that were formed spontaneously encapsulated larger quantities of calcein than liposomes that were formed *via* extrusion (both SiPCs and commercially available lipids), indicating that the extrusion process results in the loss of the material being entrapped and decreased entrapment efficiency. Although the percentage of calcein released was virtually identical across liposome samples (extruded and non-extruded), the greater entrapment efficiency of the spontaneously formed liposomes ultimately results in a greater payload delivery.

Received 27th November 2020

Accepted 29th March 2021

DOI: 10.1039/d0ra10052h

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

## Introduction

One of the ongoing avenues of research within the pharmaceutical industry is the design and development of effective drug delivery systems.<sup>1</sup> Many different modalities for the delivery of bioactive compounds have been developed including those based on polysaccharides,<sup>2</sup> proteins,<sup>3,4</sup> nanoparticles,<sup>5,6</sup> and emulsions<sup>7–9</sup> to name but a few. In principle, drug delivery systems offer the capacity to enhance the efficacy of therapeutic agents by increasing the physiological concentration of these agents, as well as allowing therapeutic agents to be targeted to specific subcellular locations. Ideally, a drug candidate would be delivered for a desired amount of time, while minimizing deleterious side effects to surrounding healthy tissues.<sup>10–12</sup>

Liposomes were first approved as nanoscale vehicles for clinical use in 1995 and are of particular interest in the area of drug delivery technology.<sup>13–20</sup> Liposomes have been shown to be excellent candidates for the controlled release of therapeutic agents, particularly in the fight against cancer, although they are not without their drawbacks.<sup>21,22</sup> The success of liposomes as delivery systems can be traced to their amphipathic characteristics which allows for the selective encapsulation of drugs

with varying lipophilicities; hydrophobic drugs can be entrapped within the fatty acid tails of the lipid bilayer while hydrophilic drugs can be solubilized for encapsulation within the hydrophilic inner core.<sup>17,23</sup> Not only can therapeutics with differing solubilities be encapsulated, but specific cells or organs can be targeted to limit or reduce potential harmful side effects caused by the distribution of the drug to non-targeted tissues.<sup>24</sup> Lipids with long chain (*i.e.*, >10 carbon atoms in their tails) tend to form multilamellar vesicles (MLVs) rather than unilamellar vesicles (ULVs). Although MLVs can be used to entrap and deliver various types of molecules, they tend to have shorter circulation half-lives.<sup>25,26</sup>

There have been a number of reports in the literature examining the addition of silicon-based compounds, most notably silicones, to liposome structures.<sup>27–29</sup> These silicon-based compounds were not part of the lipids themselves but were added to stabilize/protect the liposomal structures. In 1987 Thompson and co-workers reported the first chlorosilane-modified lipid followed nearly 25 years later by a trialkoxysilane-modified lipid synthesized by Yasuhara *et al.*<sup>30,31</sup> These silane moieties were not added to the lipids to change the overall properties of the lipids but were respectively added to facilitate binding of the lipid to a solid support and incorporation of the lipid into a sol-gel reaction.

It was not until 2017 that siloxane moieties were first grafted onto lipid structures with the express purpose of modifying the lipids' interfacial behaviour.<sup>32–34</sup> Siloxane-phospholipids (SiPCs) possessing identical lipid tail structures to biologically relevant lipid species self-assemble in aqueous media to form low dispersity, unilamellar vesicles (ULVs) that are on average 120 nm

<sup>a</sup>Department of Chemistry, Centre for Biotechnology, Brock University, 1812 Sir Isaac Brock Way, St. Catharines, Ontario, Canada. E-mail: pzelisko@brocku.ca

<sup>b</sup>Department of Biological Sciences, Centre for Biotechnology, Brock University, 1812 Sir Isaac Brock Way, St. Catharines, Ontario, Canada

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0ra10052h

‡ Current address: Loyalist College, Belleville, Ontario, Canada.



in diameter, unlike natural phosphocholines such as 1,2-dipalmitoyl-*sn*-glycero-3-phosphocholine (DPPC), 1,2-dioleoyl-*sn*-3-glycerophosphocholine (DOPC), or 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine (POPC), which typically form larger (>200 nm) multilamellar liposomes. Hybrid SiPCs, possessing a siloxane fatty acid tail in the *sn*-2 position and an aliphatic fatty acid tail in the *sn*-1 position, self-assembled into ULVs or multilamellar vesicles (MLVs) depending on the chain length of the *sn*-1 fatty acid. Fatty acids with a C<sub>8</sub> to C<sub>14</sub> chain length provided ULVs (Fig. 1).<sup>34</sup> When palmitic acid (C<sub>16</sub>), or stearic acid (C<sub>18</sub>) were incorporated at the *sn*-1 position, SAXS analysis revealed the presence of MLVs as well as ULVs.<sup>34</sup> Liposomes derived from hybrid SiPCs generally do not exhibit any detectable thermotropic phase transitions between 5 °C and 60 °C. The exception to this was the SiPC, which had stearic acid in the *sn*-1 position and displayed a phase transition temperature at 17 °C. The absence of phase transitions suggests that SiPC liposomes are comparable to liposomes composed of phosphocholines (PCs) such as POPC, DOPC with unsaturated fatty acids, or the archaeobacterial PC 1,2-diphytanoyl-*sn*-glycero-3-phosphocholine (DPhyPC).<sup>35–38</sup>

The suitability of artificial liposomes for drug delivery purposes is largely dependent on the specific release kinetics of

the bilayer. Transport across the bilayer is controlled by the polarity of the encapsulant, as well as the permeability and fluidity of the liposomal bilayer, bilayer thickness, and the number of bilayers through which the drug must migrate.<sup>39</sup> Drug delivery systems typically rely on diffusion-controlled processes that are dependent on the solubility of the drug and the diffusion coefficient within the release medium.<sup>39</sup>

Calcein, a commonly employed fluorophore used as a model drug in release studies involving liposomal structures, is a negatively charged, water soluble fluorescent probe that self-quenches at concentrations above 70 mM. Calcein has been used in examining release kinetics from phosphocholine-derived liposomes to characterize the effects of membrane fluidity, liposome size, the influence of membrane lipids, and peptide induced membrane destabilization.<sup>40,44</sup>

These SiPCs represent unique lipid structures that have the capacity to spontaneously self-assemble into unilamellar structures that are ~100 nm in diameter by simple and economic agitation. These lipids have the potential to overcome some of the negative aspects of commercially available biologically relevant lipids when it comes to the delivery of bioactive agents, namely the need for extrusion processes and the associated loss of both lipid and bioactive material.




Fig. 1 SiPCs and their capacities to spontaneously form ULVs or MLVs.<sup>32,34</sup>



In this study, we examined the release of calcein from liposomes composed of hybrid siloxane-phosphocholines to ascertain the suitability of siloxane-phosphocholines as components in drug delivery systems; POPC, DPPC, and DPhPC were included as commercially available comparators. The release of calcein was carried out at pH 4.5, 7.5 and 10.5 to mimic the different physiological environments within the human body.

## Experimental

### Materials

Calcein, Novozyme-435 (lipase B acrylic resin from *Candida antarctica* ( $\geq 5000 \text{ U g}^{-1}$ )), palmitic acid ( $\geq 95\%$  purity), 4-pentenoic acid ( $\geq 98\%$  purity), Sepharose 4B, *N,N'*-dicyclohexylcarbodiimide (DCC, 99% purity), 4-dimethylaminopyridine (DMAP, 99% purity), platinum(0)-1,3-divinyl-1,1,3,3-tetramethyldisiloxane complex solution in xylenes (Karstedt's catalyst), activated carbon, hexanes, ethyl acetate, Celite® 545, and hydrochloric acid were acquired from Sigma-Aldrich (Oakville, Ontario, Canada). 1-Palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine (POPC), 1,2-dipalmitoyl-*sn*-glycero-3-phosphocholine (DPPC), and 1,2-diphytanoyl-*sn*-glycero-3-phosphocholine (DPhPC) were acquired from Avanti Polar Lipids Inc. (Alabaster, Alabama, USA). Glycerophosphocholine (GPC) was acquired from Toronto Research Chemicals (Toronto, Ontario, Canada). 1,1,3,3,3-Pentamethyldisiloxane was acquired from Gelest, Inc. (Morristown, PA, USA). Chloroform-*d* (99.8% deuterated) and methanol-*d*<sub>4</sub> (MeOH-*d*<sub>4</sub>) were obtained from Cambridge Isotope Laboratories, Inc. (Landover, MD, USA). Triton® X-100 was obtained from Alfa Aesar (Ward Hill, MA, USA). Tris-(hydroxymethyl)aminomethane (Tris) was supplied by ACP Chemicals (Montréal, QC, Canada). Bacteria were maintained as stock cultures on Difco Nutrient Agar (NA; Becton-Dickson). Test samples were grown in Difco Nutrient Broth (NB). All materials were used as received unless otherwise stated.

### Synthesis of lipids

Hybrid SiPCs Cap-ValDS-PC 1, Cpc-ValDS-PC 2, Lau-ValDS-PC 3, Myr-ValDS-PC 4, Pal-ValDS-PC 6, and Ste-ValDS-PC 7 were synthesized as previously described.<sup>34</sup> The general procedures for the synthesis of lyso-PCs and hybrid SiPCs are included below. More detailed syntheses and complete spectroscopic characterization can be found in the ESI.†

**Synthesis of lyso-PCs.** A Teflon flask was charged with  $\alpha$ -glycerophosphocholine and 20 equivalents of a chosen fatty acid and melted together at 65 °C. N435 was added and stirred for 5 min at 1000 mbar, after which time the pressure was reduced to 150 mbar for 72 h with stirring. The reaction was quenched by cooling to room temperature and diluting with 10 mL of 9 : 1 CHCl<sub>3</sub> : MeOH. The immobilized lipase beads were removed by filtering the mixture through a medium porosity, glass-fritted Büchner funnel. The solvents were removed *in vacuo* to give viscous oils. The crude product was purified by column chromatography using 400 mesh silica gel, applied as a silica gel-chloroform slurry. Each column was preconditioned with 10 mL of 9 : 1 CHCl<sub>3</sub> : MeOH before

loading the crude mixture and eluting with an isocratic elution solvent of 65 : 25 : 4 CHCl<sub>3</sub> : MeOH : H<sub>2</sub>O.

**General synthesis of hybrid SiPCs.** An oven-dried flask was cooled under a nitrogen atmosphere and charged with 1-(4-carboxybutyl)-1,1,3,3,3-pentamethyldisiloxane and dissolved into 1 mL of CHCl<sub>3</sub>. To this solution were added 1.1 equivalents of DCC and 5 mol% of DMAP and the mixture was stirred at room temperature for 5 min. A solution of each lyso-PC (2 eq.) in 2 mL of CHCl<sub>3</sub> was added and the reaction mixture was stirred for 24 h. A white precipitate was filtered from the reaction mixture and the solvent was removed under reduced pressure. The crude residue was purified by column chromatography using 200–400 mesh silica gel (20 g) after being suspended in CHCl<sub>3</sub>. The column was preconditioned with 10 mL of 9 : 1 CHCl<sub>3</sub> : MeOH and the eluted with 65 : 25 : 4 CHCl<sub>3</sub> : MeOH : H<sub>2</sub>O to give hybrid SiPCs as opaque gels. Detailed synthetic information can be found in the ESI.†

### Ultraviolet/visible (UV/vis) and fluorescence spectroscopy

UV-vis spectra were recorded using a SpectroVis Plus spectrometer/fluorimeter. Wavelength ( $\lambda_{\text{max}}$ ) selection depended on the nature of the sample (*i.e.*, the pH of the buffer solution). The wavelength of maximum absorbance ( $\lambda_{\text{max}}$ ) for calcein is typically reported as 490 nm, however, the emission intensity has been shown to vary with pH.<sup>39</sup> Since we were interested in examining the release of calcein at various pH values, the emission wavelengths ( $\lambda_{\text{em}}$ ) values were experimentally determined for calcein at pH 4.5, 7.5, and 10.5 (Table 1) and used as appropriate in the subsequent experiments – for all pH values the samples were excited at 405 nm. Absorption and emission spectra were analyzed using the Logger Pro v3.10.2 software platform.

### General method for liposome preparation

Commercially available phospholipids (100 mg) were dissolved into 1.0 mL of chloroform, aliquoted into 10 mg portions in glass ampules and dried under vacuum in a desiccator containing Drierite® for 24 h to produce lipid thin films. A similar methodology was used to prepare thin films of SiPCs – the volume of chloroform was adjusted based on the available mass of the particular SiPC. Ampules were heat-sealed and subsequently stored at –20 °C. Lipid films were rehydrated with 0.7 mL of a 100 mM calcein solution (5 mL of the pH 7.5 Tris buffer to which calcein was added) to make a 20 mM solution of the lipid. The sample was then vortexed at 1500 rpm for 10 min at room temperature to initiate liposome formation (non-extruded liposomes). Samples of liposomes were additionally

**Table 1** Maximum emission wavelengths for calcein at experimentally relevant pH values following excitation at 405 nm

pH	$\lambda_{\text{em}}$
4.5	526
7.5	523
10.5	535



extruded through a 100 nm Nanosizer MINI Sterile Extruder (T&T Scientific Corporation, Knoxville, TN, USA) (extruded liposomes). The extruder was conditioned with 10 mL of Tris buffer (pH 7.5, 50 mM Tris, 100 mM NaCl). Extrusion was performed with 31 passages through the membrane.

### General method for liposome purification

Liposomes were isolated from free calcein using size exclusion chromatography (SEC) on Sepharose 4B. A slurry of Sepharose 4B was prepared applying 5 mL of Sepharose into a polypropylene column. The column was then conditioned with 10 mL of Tris buffer (pH 7.5, 50 mM Tris, 100 mM NaCl) prior to loading the liposome suspension. The calcein-containing liposomes were eluted with Tris buffer to remove unincorporated calcein from liposomes. Unincorporated calcein eluted from the column first, as evidenced by a bright green coloured solution, followed by calcein-containing liposomes, deep red in colour.

### Dynamic light scattering (DLS)

Siloxane phosphocholines were diluted to a concentration of approximately 30 mg mL<sup>-1</sup> in an ultrapure H<sub>2</sub>O suspension and vortexed for 15 minutes. The DLS (Protein Solutions Dyna Pro Light Scattering System and Temperature Controlled Micro-sampler) was calibrated using silver nanoparticles in a 70% solution of ethanol from Cytodiagnosics that are 100 nm in diameter with a concentration of 0.02 mg mL<sup>-1</sup> and have a refractive index of 0.135. All siloxane phosphocholine measurements were obtained using a quartz cuvette with a 1 cm pathlength. The refractive index was set to 0.16 and the radius was calculated using a globular protein model.

### Liposome release studies

The liposomes formulated with calcein were analyzed for calcein release immediately after SEC. Liposome suspensions (30 μL) were combined with 3 mL of Tris buffer (50 mM Tris, 100 mM NaCl) at three different pH values (pH 4.5, 7.5, and 10.5) in 5 mL polystyrene fluorescence cuvettes (Spectrecology, Dunedin, FL, USA) using a SpectroVis Plus Fluorimeter with an excitation wavelength of 405 nm with the appropriate maximum emission wavelength for the pH value (Table 2) being recorded. The release profile was then calculated using eqn (1):

$$RF\% = 100 \left( \frac{I_t - I_0}{I_{\max} - I_0} \right) \quad (1)$$

where  $I_0$ ,  $I_t$  and  $I_{\max}$  are the fluorescence intensities of calcein at time 0, time  $t$ , and after the application of 1.3 mL of 3% Triton X-100. The actual  $I_{\max}$  intensity was corrected using the dilution factor of each cuvette after Triton X-100 application. The  $I_{\max}$  values were utilized to calculate the total concentration of calcein within each sample.

### SiPC lipid stability

The lipid (POPC or Myr-ValDS-PC, 10 mg) was added to 1 mL of buffer (pH 4.5, 7.5, or 10.5). Once suspended the lipid was

Table 2 Naming convention for fatty acid tail components of SiPCs

Total carbon number	Trivial name	Three-letter abbreviation
C <sub>1</sub>	Formic acid	For
C <sub>2</sub>	Acetic acid	Ace
C <sub>3</sub>	Propionic acid	Pro
C <sub>4</sub>	Butyric acid	But
C <sub>5</sub>	Valeric acid	Val
C <sub>6</sub>	Caproic acid	Cpr
C <sub>7</sub>	Enanthic acid	Ena
C <sub>8</sub>	Caprylic acid	Cap
C <sub>9</sub>	Pelargonic acid	Pel
C <sub>10</sub>	Capric acid	Cpc
C <sub>11</sub>	Hendecanoic acid	Hen
C <sub>12</sub>	Lauric acid	Lau
C <sub>13</sub>	Tridecyl acid	Try
C <sub>14</sub>	Myristic acid	Myr
C <sub>15</sub>	Pentadecyl acid	Pen
C <sub>16</sub>	Palmitic acid	Pal
C <sub>17</sub>	Margaric acid	Mar
C <sub>18</sub>	Stearic acid	Ste

extruded 31 times and allowed to sit at room temperature for 24 h after which time the buffer was removed *in vacuo*. Following removal of the buffer the lipid was suspended in either CDCl<sub>3</sub> (POPC) or MeOD-*d*<sub>4</sub> (Myr-ValDS-PC) and the corresponding <sup>1</sup>H NMR spectra were acquired and compared with the virgin lipids.

### General methods for microbial toxicity studies

Bacteria were grown overnight in NB in a shaking water bath at 28 °C. Hybrid siloxane-phosphocholine lipids (50 μg mL<sup>-1</sup>, 25 μg mL<sup>-1</sup>, 12.5 μg mL<sup>-1</sup>, 6.25 μg mL<sup>-1</sup>, 3.125 μg mL<sup>-1</sup>, and 0 μg mL<sup>-1</sup>) were added to microtitre plate wells containing sufficient bacteria (*Erwinia amylovora*, *Pantoea agglomerans*, *Bacillus subtilis*, *Streptococcus saprophyticus*) in NB to give an optical density (OD<sub>595</sub>) of approximately 0.1 (between 5 × 10<sup>6</sup> and 1 × 10<sup>7</sup> cells per mL depending upon the species). Each test was repeated eight times. Test plates were incubated at 28 °C with gentle agitation to prevent cell settling. The optical density of bacterial samples was measured at 595 nm in an iMark Microplate Absorbance Reader (Bio-Rad, Mississauga ON) at 0, 2, 4, 6, and 24 h.




Fig. 2 The foundational components for hybrid SiPC nomenclature.



## Results and discussion

### Siloxane-containing lipid structures

We have been studying siloxane phosphocholines which feature at least one fatty acid tail that has been modified to contain a pentamethyldisiloxane moiety. We previously reported the synthesis of double tailed siloxane-phosphocholines which featured the enzymatic esterification of siloxane-containing carboxylic acids with glycerol, to generate 1,2- and 1,3-substituted diacylglycerides, which was followed by installation of the phosphocholine head group.<sup>31</sup> Both 1,2-SiPC and 1,3-SiPC were found to self-assemble into ULVs with low size dispersity.<sup>30</sup> Employing a lipase-mediated esterification to produce lyso-PCs ( $C_8$  to  $C_{18}$ ) substituted in the *sn*-1 position, we then installed the second fatty acid into the *sn*-2 position using a modification of the Steglich esterification to provide access to a library of SiPCs (Fig. 1).

To aid in the identification of these unique species, a nomenclature system based on a general A-BC-D system (Fig. 2) was developed where “A” represents the trivial name of the carboxylic acid in the *sn*-1 position, “B” represents the trivial name for the carboxylic acid portion at the *sn*-2 position, “C” represents the silicon-containing portion at the *sn*-2 position, and “D” represents the head group at the *sn*-3 position.

The conventional two-letter abbreviation (*e.g.*, PC, PE, PG, *etc.*) for the phosphate head groups of biologically relevant phospholipids is employed for “D”. The silicon-containing portion of the lipid is abbreviated “XS”, where “X” represents the first letter of the quantifier (*i.e.*, di-, tri-, *etc.*) indicating the extent of the siloxane unit, “S”. The trivial name for the carboxylic acid moieties is abbreviated as outlined in Table 2.

We synthesized six hybrid SiPCs (Fig. 1) to examine the release of calcein from 100 nm extruded vesicles and non-extruded liposomes at three different pH values (4.5, 7.5, and

10.5). POPC, DPPC, and DPhPC (Fig. 3), three commercially available phospholipids that have been utilized in release studies and to mimic biological membranes, were included for comparison.<sup>45–53</sup> It was of particular interest to include DPhPC in this study given the similarities that had been observed between this lipid and siloxane-containing lipids.<sup>31</sup>

### Bacterial toxicity

Four bacterial species (*Erwinia amylovora*, *Pantoea agglomerans*, *Bacillus subtilis*, *Streptococcus saprophyticus*) were used to examine the microbial toxicity of the hybrid siloxane-




Fig. 3 Commercially available lipids used as comparators for the calcein entrapment and release experiments.




Fig. 4 Growth of bacterial cultures on hybrid SiPC lipids. OD595 readings of time 0 and time 24 h cultures grown in  $50 \mu\text{g mL}^{-1}$  lipid.



**Table 3** DLS determined diameters of liposomes based on hybrid siloxane lipids

Lipid	Diameter (nm)	%Polydispersity
Cap-ValDS-PC	97.1	0.1
Cpc-ValDS-PC	168.3	0.1
Lau-ValDS-PC	364.3	11.8
Myr-ValDS-PC	106.3	0.1
Pal-ValDS-PC	94.7	0.1
Ste-ValDS-PC	99.6	0.1

phosphocholine molecules at concentrations of 50.00  $\mu\text{g mL}^{-1}$ , 25.00  $\mu\text{g mL}^{-1}$ , 12.50  $\mu\text{g mL}^{-1}$ , 6.250  $\mu\text{g mL}^{-1}$ , and 3.125  $\mu\text{g mL}^{-1}$ . Toxicity trials were replicated eight-fold and some of the average values are reported in Fig. 4 for example. All of the species tolerated all of the hybrid siloxane-phosphocholine compounds indicating that, for these bacteria at the very least, the lipid compounds were not antimicrobial. At this point it is not clear whether the lipids are being incorporated into the membrane structure or if the lipids are simply being used as a nutrient source by the bacteria. The tolerance of bacteria for the lipids suggested that liposomes based on the hybrid siloxane-phosphocholine molecules have the potential to behave as drug delivery vehicles.

**Table 4** The amount of calcein entrapped in and released from liposomes at various pH values

Liposome	pH	Avg. calcein entrapped ( $\text{mg mL}^{-1}$ )	Avg. calcein released after 6.5 h (%)	Avg. calcein released after 6.5 h ( $\text{mg mL}^{-1}$ )
Cap-ValDS-PC (non-extruded)	4.5	0.029	58	0.017
	7.5		48	0.014
	10.5		66	0.019
Cap-ValDS-PC (extruded)	4.5	0.009	74	0.007
	7.5		93	0.009
	10.5		63	0.006
Cpc-ValDS-PC (non-extruded)	4.5	0.029	45	0.019
	7.5		66	0.019
	10.5		69	0.020
Cpc-ValDS-PC (extruded)	4.5	0.011	78	0.008
	7.5		93	0.010
	10.5		73	0.008
Lau-ValDS-PC (non-extruded)	4.5	0.026	62	0.016
	7.5		64	0.016
	10.5		71	0.018
Lau-ValDS-PC (extruded)	4.5	0.009	81	0.007
	7.5		97	0.008
	10.5		70	0.006
Myr-ValDS-PC (non-extruded)	4.5	0.032	68	0.022
	7.5		64	0.020
	10.5		68	0.022
Myr-ValDS-PC (extruded)	4.5	0.017	72	0.012
	7.5		78	0.014
	10.5		63	0.011
Pal-ValDS-PC (non-extruded)	4.5	0.037	62	0.023
	7.5		59	0.022
	10.5		60	0.022
Pal-ValDS-PC (non-extruded)	4.5	0.013	68	0.009
	7.5		87	0.012
	10.5		60	0.008
Ste-ValDS-PC (non-extruded)	4.5	0.022	56	0.012
	7.5		56	0.012
	10.5		58	0.013
Ste-ValDS-PC (extruded)	4.5	0.012	74	0.009
	7.5		93	0.011
	10.5		63	0.007
POPC (extruded)	4.5	0.013	70	0.009
	7.5		77	0.010
	10.5		51	0.006
DPPC (extruded)	4.5	0.016	64	0.010
	7.5		75	0.012
	10.5		49	0.008
DPhPC (extruded)	4.5	0.011	65	0.007
	7.5		86	0.009
	10.5		58	0.006



### Dynamic light scattering

Symmetrical, double-tailed SiPCs have been shown to spontaneously self-assemble into ULVs of approximately 120–200 nm diameters upon hydration with ultra-pure water.<sup>32</sup> Furthermore, we have shown that these hybrid SiPCs also self-assemble into ULVs.<sup>34</sup> The sizes of vesicles formed from hybrid SiPCs were analyzed by DLS and the results are summarized in Table 3. Hybrid SiPCs were found to self-assemble into vesicles of ~100 nm in diameter, with the exception of Cpc-ValDSPC (2), which was determined to be 168 nm in diameter and Lau-ValDSPC (3), which had a diameter of 364 nm.

### Calcein entrapment/release studies

The tendency of calcein to self-quench at concentrations over 70 mM makes it a convenient compound for probing the release capacity of liposomal systems.<sup>39–43</sup> When entrapped within the liposomes the calcein should produce little to no fluorescence. However, upon exiting the liposomes the calcein will become more dilute and will fluoresce.<sup>38–41</sup> The increase in fluorescence intensity serves as an indicator for the rate of release from the liposomes.

We have previously reported that Cap-ValDS-PC 1, Cpc-ValDS-PC 2, Lau-ValDS-PC 3, and Myr-ValDS-PC 4 spontaneously form ULVs when dispersed in aqueous media and it was of interest to examine the release of calcein from both extruded and non-extruded liposomal systems. Since the benchmark lipids (POPC, DPPC, and DPhPC) are known to spontaneously form MLVs,<sup>32,54</sup> these lipids were all extruded to form ULVs.

Calcein release profiles were very similar in overall appearance across the lipids that were studied (see ESI†), with the vast majority of the liposomes displaying a burst release period followed by a plateau or slower release rate; linear release profiles were typically observed over the first 60–90 min. In these liposomal systems, the release of calcein is best described by the migration of the molecule through the lipid bilayer into the surrounding medium. The movement of calcein across the bilayer does not require the input of energy and relies on the concentration gradient across the lipid membrane.<sup>39</sup> Previous work has suggested that calcein migrates through the hydrocarbons portion of the lipid bilayer rather than through pores found in the lipid membrane.<sup>42</sup> The observed differences in the rate of release, monitored as an increase in fluorescence can be attributed to the overall ionization state of calcein, the differences in the physical characteristics of the lipid bilayer, the area per lipid, and the electrochemical gradient across the lipid membrane.<sup>38</sup> Unsaturated lipids generally possess a larger mean molecular area compared to saturated lipids of the same chain length, and tend to release more of their entrapped cargo.<sup>39</sup> SiPCs more closely resemble unsaturated lipids, than saturated lipids, architecturally, and typically have larger molecular volumes than either saturated or unsaturated lipids of comparable chain length.<sup>32,34</sup>

Not only was it of interest to examine the release profiles of the various liposomal systems, but it was also of interest to




Fig. 5 Calcein entrapment efficiency in the liposomal systems using a pH 7.5 buffer.



correlate these release profiles with the amount of material that was actually released from the liposomes (Table 4). For all of the hybrid SiPC liposomal systems, save for those based on Myr-ValDS-PC, the non-extruded liposomes entrapped a greater amount of calcein than the extruded liposomes (Fig. 5 and Table 4).

In all instances the SiPC liposomes that had been extruded released a greater percentage of their cargo than the non-extruded liposomes (Table 4). Extruded vesicles tend to be smaller than unextruded vesicles, leading to decreased packing between lipid molecules. Shimanouchi *et al.* suggested that liposome size contributes to the permeability of a lipid bilayer.<sup>42</sup>

In spite of the propensity for Pal-ValDS-PC 6 and Ste-ValDS-PC 7 to spontaneously form MLVs (*i.e.*, larger vesicles) in addition to ULVs. Presumably the majority of the entrapped calcein in these liposomes is found in the central aqueous core of the MLVs and the overall release of calcein would be retarded by the increasing number of lipid bilayers standing between the calcein and the external aqueous environment. In some instances, the number of bilayers present is larger owing to smaller vesicles nested inside of larger vesicles, potentially even after extrusion.<sup>55</sup>

However, in spite of releasing a lower percentage of the entrapped calcein, the non-extruded liposomes, in all cases, both entrapped and subsequently released a greater overall amount of calcein than the liposomes that had not been subjected to extrusion (Table 4). This suggests that calcein is lost during the extrusion process and is therefore not incorporated into the liposomes. Extrusion of liposomes through a 100 nm filter reduces not only the size of the resulting liposomes, but as a result, the packing of the lipid molecules is reduced. Reduced lipid packing would account for the higher percentage of calcein that was released for the extruded liposomes.<sup>39</sup>

### Degradation of the lipid membrane

The effect of pH on the calcein release was examined. Previous work had shown that in the simulated gastric and duodenal digestion of POPC, lowered pH values resulted in a rapid release of calcein.<sup>39</sup> The physical integrity of the liposome remained the same over the two-hour experimental time frame. Upon the addition of bile salts and increasing the




Fig. 6 <sup>1</sup>H NMR spectra of virgin POPC (purple), POPC exposed to pH 4.5 buffer (green), pH 7.5 buffer (red), and pH 10.5 buffer (blue). Samples possess some entrained water.




Fig. 7 <sup>31</sup>P NMR spectra of virgin POPC (purple), POPC exposed to pH 4.5 buffer (green), pH 7.5 buffer (red), and pH 10.5 buffer (blue).

pH to 6.5 to mimic duodenal digestion, liposome disruption and the subsequent burst release of calcein was observed. Contrasting these results, we have found that extruded hybrid SiPC liposomes, as well as extruded liposomes of POPC, DPPC, and DPhyPC, released a lower percentage of their calcein at pH 4.5 and 10.5 than at 7.5, suggesting that there is no liposomal degradation at these pH values (see ESI†). Non-extruded liposomes did not generally indicate such differences across pH values.

In an effort to gain insights into the release mechanism(s) from the SiPC liposomes, the structural stability of the lipids in acid media were determined; POPC and Myr-ValDS-PC were utilized as models for the commercially available lipids and for the hybrid SiPCs explored in this paper, respectively. The lipid was exposed to buffer (pH 4.5, 7.5, or 10.5) for a period of 24 h. After this time the buffer was removed *via* freeze drying to yield the isolated lipid species. <sup>1</sup>H and <sup>31</sup>P NMR analysis of the isolated lipid material (without any purification) produced virtually identical spectra to the pure, virgin, lipid compounds (Fig. 6–9); residual water can be observed in the <sup>1</sup>H NMR spectra of both lipids. This data indicated that there was no significant degradation of the lipid structures upon exposure to the buffers used as the release media in these experiments. This lack of observable degradation supports the assertion that lipid degradation does not play a role in calcein being released from liposomes and that release of the entrapped material occurred *via* simple diffusion through the membrane.




Fig. 8 <sup>1</sup>H NMR spectra of virgin Myr-ValDS-PC (purple), Myr-ValDS-PC exposed to pH 4.5 buffer (green), pH 7.5 buffer (red), and pH 10.5 buffer (blue). Samples possess some entrained water.






Fig. 9  $^{31}\text{P}$  NMR spectra for virgin Myr-ValDSPC (purple), Myr-ValDSPC exposed to pH 4.5 buffer (green), pH 7.5 buffer (red), and pH 10.5 buffer (blue).

## Conclusions

Hybrid siloxane-phosphocholine liposome structures did not inhibit the growth of *Erwinia amylovora*, *Pantoea agglomerans*, *Bacillus subtilis*, or *Streptococcus saprophyticus*. A model compound, calcein, was efficiently entrapped within both extruded and non-extruded liposomes based on hybrid SiPC systems, even in comparison with the control systems. Not surprisingly, the non-extruded liposomes ultimately possessed greater entrapment efficiency than their extruded counterparts, presumably because material was lost on the membrane and in the syringes during the extrusion process. Both the extruded and non-extruded hybrid SiPC liposomes demonstrated moderate to high (>60%) absolute releases of their entrapped cargo; for many of the hybrid SiPC systems this release rate was somewhat greater than the release observed for the model, extruded, biologically relevant, liposomes based on POPC, DPPC, and DPhyPC. Given the propensity for the majority of the hybrid SiPC compounds to spontaneously form ULVs that are ~100 nm in diameter, these compounds represent a useful tool for not only delivering biologically active compounds, but also for the efficient entrapment of said compounds when compared to commercially available biologically relevant lipids currently being explored for the delivery of active compounds.

## Conflicts of interest

There are no conflicts of interest to declare.

## Acknowledgements

The authors would thank the Natural Sciences and Engineering Research Council (NSERC) of Canada and the Brock University Advanced Biomanufacturing Centre (ABC) for funding. ZR was the recipient of an NSERC Undergraduate Student Research Award (USRA). The authors would also like to thank Prof. T. Yan (Brock University) and Jesse Vanloon (Brock University) for their assistance with the DLS.

## Notes and references

1 D. Jain, S. S. Mahammad, P. P. Sing and R. Kodipyaka, *Drug Dev. Ind. Pharm.*, 2019, **45**, 1403.

- 2 T. G. Barclay, C. M. Day, N. Petrovsky and S. Garg, *Carbohydr. Polym.*, 2019, **221**, 94.
- 3 P. H. L. Tran, W. Duan, B.-J. Lee and T. T. D. Tran, *Int. J. Pharm.*, 2019, **566**, 557.
- 4 G. Yang, Y. Lu, H. N. Bomba and Z. Gu, *Curr. Med. Chem.*, 2019, **26**, 1377.
- 5 D. Warther, Y. Xiao, F. Li, Y. Wang, K. Huffman, W. R. Freeman, M. Sailor and L. Cheng, *Drug Delivery*, 2018, **25**, 1537.
- 6 W. Chen, C. A. Glackin, M. A. Horwitz and J. I. Zink, *Acc. Chem. Res.*, 2019, **52**, 1531.
- 7 P. M. Zelisko, K. K. Flora, J. D. Brennan and M. A. Brook, *Biomacromolecules*, 2008, **9**, 2153.
- 8 P. M. Zelisko, A. Lopez Aguilar and M. A. Brook, *Langmuir*, 2007, **23**, 3620.
- 9 P. M. Zelisko and M. A. Brook, *Langmuir*, 2002, **18**, 8982.
- 10 M. Piffoux, A. Nicolás-Boluda, V. Mulens-Arias, S. Richard, G. Rahmi, F. Gazeau, C. Wilhelm and A. K. A. Silva, *Adv. Drug Delivery Rev.*, 2019, **138**, 247.
- 11 J. M. Gudbergsson, K. Jönsson, J. B. Simonsen and K. B. Johnsen, *Adv. Drug Delivery Rev.*, 2019, **306**, 108.
- 12 J. C. Cuggino, E. R. O. Blanco, L. M. Gugliotta, C. I. A. Igarzabal and M. Calderón, *Adv. Drug Delivery Rev.*, 2019, **307**, 221.
- 13 V. Nekkanti and S. Kalepu, *Pharm. Nanotechnol.*, 2015, **3**, 35.
- 14 S. S. Lokhande, *Pharma Sci. Monit.*, 2018, **9**, 188.
- 15 M. Singh, S. Devi, V. S. Rana, B. B. Mishra, J. Kumar and V. Ahluwalia, *J. Microencapsulation*, 2019, **36**, 215.
- 16 C. Zylberberg and S. Matosevic, *Drug Delivery*, 2016, **23**, 3319.
- 17 J.-S. Kim, *J. Pharm. Invest.*, 2016, **46**, 387.
- 18 N. Oku, *Biol. Pharm. Bull.*, 2017, **40**, 119.
- 19 C. Y. Wong, H. Al-Salami and C. R. Dass, *Int. J. Pharm.*, 2018, **549**, 201.
- 20 A. S. Abu Lila and T. Ishida, *Biol. Pharm. Bull.*, 2017, **40**, 1.
- 21 V. Sreekanth and A. Bajaj, *ACS Biomater. Sci. Eng.*, 2019, **5**, 4148–4166.
- 22 H. Daraee, A. Etemadi, M. Kouhi, S. Alimizalu and A. Akbarzadeh, *Artif. Cells, Nanomed., Biotechnol.*, 2016, **44**, 381.
- 23 T. Imai, Y. Takahashi, M. Nishikawa, K. Kato, M. Morishita, T. Yamashita, A. Matsumoto, C. Charoenviriyakul and Y. Takakura, *J. Extracell. Vesicles*, 2015, **4**, DOI: 10.3402/jev.v4.26238.
- 24 G. Bozzuto and A. Molinari, *Int. J. Nanomed.*, 2015, **10**, 975.
- 25 R. L. Juliano and D. Stamp, *Biochem. Biophys. Res. Commun.*, 1973, **63**, 651.
- 26 D. B. Fenske and P. R. Cullis, *Phys. Can.*, 2004, **60**, 187.
- 27 J. Lewandowska, M. Kępczyński, J. Bednar, E. Rząd, V. Moravcikova, B. Jachimska and M. Nowakowska, *Colloid Polym. Sci.*, 2010, **288**, 37.
- 28 V. J. Mohanraj, T. J. Barnes and C. A. Prestidge, *Int. J. Pharm.*, 2010, **392**, 285.
- 29 J. Lewandowska-Łańucka, K. Mystek, A. Gilarska, K. Kamiński, M. Romek, B. Sulikowski and M. Nowakowska, *Colloids Surf., B*, 2016, **143**, 359.
- 30 R. K. Kallury, U. J. Krull and M. Thompson, *J. Org. Chem.*, 1987, **52**, 5478.



- 31 K. Yasuhara, S. Miki, H. Nakazono, A. Ohta and J. Kikuchi, *Chem. Commun.*, 2011, **47**, 4691.
- 32 M. B. Frampton, D. Marquardt, I. Letovsky-Papst, G. Papst and P. M. Zelisko, *Langmuir*, 2017, **33**, 4948.
- 33 M. B. Frampton and P. M. Zelisko, *Eur. J. Lipid Sci. Technol.*, 2017, **119**, DOI: 10.1002/ejlt.201600248.
- 34 M. B. Frampton, M. H. Nguyen, M. DiPasquale, R. Dick, D. Marquardt and P. M. Zelisko, *Chem. Phys. Lipids*, 2018, **216**, 1.
- 35 H. Binder and K. Gawrisch, *Biophys. J.*, 2001, **81**, 969.
- 36 R. Thakur, A. Das and A. Charaborty, *RSC Adv.*, 2014, **4**, 14335.
- 37 A. Das, C. Adhikari and A. Chakraborty, *Langmuir*, 2016, **32**, 8889.
- 38 A. Yasmann and S. Sukharev, *Langmuir*, 2015, **31**, 350.
- 39 B. Maherani, E. Arab-Tehrany, A. Kheiriloomoo, D. Geny and M. Linder, *Biochimie*, 2013, **95**, 2018.
- 40 H. Heerklotz and J. Seelig, *Eur. Biophys. J.*, 2007, **36**, 305.
- 41 T. Wiprecht, M. Dathe, R. M. Epand, M. Beyermann, E. Krause, W. L. Maloy, D. L. MacDonald and M. Bienert, *Biochemistry*, 1997, **36**, 12869.
- 42 T. Shimanouchi, H. Ishii, N. Yoshimoto, H. Umakoshi and R. Kuboi, *Colloids Surf., B*, 2009, **73**, 156.
- 43 G. D. Sprott, C. J. Dicaire, L. P. Flemming and G. P. Patel, *Cells Mater.*, 1996, **6**, 143.
- 44 J. Davidsen, K. Jørgensen, T. L. Andresen and O. G. Moritsen, *Biochim. Biophys. Acta*, 2003, **1609**, 95.
- 45 S. Punnamaraju, H. You and A. J. Steckl, *Langmuir*, 2012, **28**, 7657.
- 46 N. Essam Eldin, A. S. Abu Lila, K. Kawazoe, H. M. Elnahas, M. A. Mahdy and T. Ishida, *Eur. J. Pharm. Sci.*, 2016, **81**, 60.
- 47 A. Rodríguez-Pulido, A. I. Kondrachuk, D. K. Prusty, J. Gao, M. A. Loi and A. Herrmann, *Angew. Chem., Int. Ed.*, 2013, **52**, 1008.
- 48 C. F. de Freitas, I. R. Calori, A. L. Tessarob, W. Caetano and N. Hioka, *Colloids Surf., B*, 2019, **181**, 837.
- 49 N. Pippa, A. Meristoudi, S. Pispas and C. Demetzos, *Int. J. Pharm.*, 2015, **485**, 374.
- 50 S. Damiati, An. Scheberl, S. Zayni, S. A. Damiati, B. Schuster and U. B. Kompella, *Biophys. Chem.*, 2019, **251**, 106178.
- 51 B. L. Spaller, J. M. Trieu and P. F. Almeida, *J. Membr. Biol.*, 2013, **246**, 257.
- 52 T. Lu and T. L. M. ten Hagen, *Adv. Drug Delivery Rev.*, 2017, **247**, 64.
- 53 A. Svetlova, J. Ellieroth, F. Milos, V. Maybeck and A. Offenhäusser, *Langmuir*, 2019, **35**, 8076.
- 54 M.-P. Nieh, J. Katsaras and X. Q. Biochim, *Biochim. Biophys. Acta*, 2008, **1778**, 1467.
- 55 H. L. Scott, A. Skinkle, E. G. Kelley, M. N. Waxham, I. Levental and F. A. Heberle, *Biophys. J.*, 2019, **117**, 1381.

